Status:
RECRUITING
Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
Lead Sponsor:
Centre Henri Becquerel
Conditions:
Triple Negative Breast Cancer
Eligibility:
FEMALE
18-75 years
Phase:
NA
Brief Summary
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood mark...
Detailed Description
Triple-negative breast cancers (TNBC) account for approximately 15% of breast cancers, representing about 8,800 cases per year. The therapeutic management of localized TNBC is based on a multimodal st...
Eligibility Criteria
Inclusion
- Signed informed consent
- Patient with histologically proven TNBC
- Indication for neo-adjuvant chemo-immunotherapy treatment
- Age between 18 and 75
- Affiliated or beneficiary of a social protection scheme
Exclusion
- Pregnant or breast-feeding women
- Contraindication to immunotherapy
- Inflammatory breast cancer (T4d)
- Metastatic patients
- Allergies to iodine or gadolinium
- Patient with an augmentation prosthesis (for angiography/mammography)
- Claustrophobic patients
- Renal contraindication to contrast products according to SFR-CIRTACI
- Ferromagnetic material
- Uncontrolled diabetes (blood glucose \>10 mmol/L)
- Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).
- Patient under guardianship, curatorship or safeguard of justice
Key Trial Info
Start Date :
May 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 28 2029
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT06879704
Start Date
May 28 2025
End Date
November 28 2029
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Henri Becquerel
Rouen, France, 76038